Loading…
Loading…
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company's stock, valued at approximately $1,158,000. A
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.
ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 133,000 shares of the biotechnology company's stock, valued at approximately $1,330,000. ADAR1 Capital Management LLC owned